Chk2, Blocking Peptide

CDS1; CHK2; LFS2; RAD53; hCds1; HuCds1; PP1425; CDS1; CHK2 checkpoint homolog; Hucds1; CHK2 checkpoint homolog (S. pombe)

For Research Use Only. Not for use in diagnostic procedures.

Liquid

200 ug/mL (lot specific)

Store Chk2 peptide at -20 degree C, stable for one year.

Small volumes of CHEK2 blocking peptide vial(s) may occasionally become entrapped in the seal of the product vial during shipment and storage. If necessary, briefly centrifuge the vial on a tabletop centrifuge to dislodge any liquid in the container`s cap. Certain products may require to ship with dry ice and additional dry ice fee may apply.

Blocking (BL)

Chk2 peptide is used for blocking the activity of Chk2 antibody.

36,157 Da

checkpoint kinase 2

serine/threonine-protein kinase Chk2; cds1 homolog; CHK2 checkpoint homolog; checkpoint-like protein CHK2

Serine/threonine-protein kinase Chk2

CDS1; CHK2; RAD53; Hucds1; hCds1  [Similar Products]

CHK2_HUMAN

In response to DNA damage and replication blocks, cell cycle progression is halted through the control of critical cell cycle regulators. The protein encoded by this gene is a cell cycle checkpoint regulator and putative tumor suppressor. It contains a forkhead-associated protein interaction domain essential for activation in response to DNA damage and is rapidly phosphorylated in response to replication blocks and DNA damage. When activated, the encoded protein is known to inhibit CDC25C phosphatase, preventing entry into mitosis, and has been shown to stabilize the tumor suppressor protein p53, leading to cell cycle arrest in G1. In addition, this protein interacts with and phosphorylates BRCA1, allowing BRCA1 to restore survival after DNA damage. Mutations in this gene have been linked with Li-Fraumeni syndrome, a highly penetrant familial cancer phenotype usually associated with inherited mutations in TP53. Also, mutations in this gene are thought to confer a predisposition to sarcomas, breast cancer, and brain tumors. This nuclear protein is a member of the CDS1 subfamily of serine/threonine protein kinases. Several transcript variants encoding different isoforms have been found for this gene. [provided by RefSeq, Apr 2012]

Chk2: a CAMK protein kinase of the Rad53 family. A cell cycle checkpoint regulator and putative tumor suppressor. It contains a forkhead-associated protein interaction domain essential for activation in response to DNA damage and is rapidly phosphorylated in response to replication blocks and DNA damage. Phosphorylates and inhibits CDC25C, preventing entry into mitosis, p53, leading to cell cycle arrest in G1, and BRCA1, restoring survival after DNA damage. Twelve splice variant isoforms have been described for human Chk2. LOF mutants cause Li-Fraumeni syndrome, a highly penetrant familial cancer phenotype also caused by p53 mutations. Familial mutations also associated with prostate and breast cancer, and mutations also seen in a variety of sporadic cancers and cell lines.

Protein type: Protein kinase, CAMK; Protein kinase, Ser/Thr (non-receptor); Kinase, protein; Tumor suppressor; EC 2.7.11.1; CAMK group; RAD53 family

Chromosomal Location of Human Ortholog: 22q12.1

Cellular Component: nucleoplasm; Golgi apparatus; PML body; chromosome, telomeric region

Molecular Function: identical protein binding; protein serine/threonine kinase activity; protein binding; protein homodimerization activity; metal ion binding; ubiquitin protein ligase binding; protein kinase binding; ATP binding

Biological Process: DNA damage induced protein phosphorylation; transcription, DNA-dependent; protein stabilization; positive regulation of transcription, DNA-dependent; protein amino acid autophosphorylation; DNA damage response, signal transduction; protein amino acid phosphorylation; regulation of transcription, DNA-dependent; DNA damage response, signal transduction resulting in induction of apoptosis; cell division; cellular protein catabolic process; double-strand break repair; DNA damage checkpoint; response to gamma radiation; regulation of protein catabolic process; G2/M transition of mitotic cell cycle; response to DNA damage stimulus

Disease: Li-fraumeni Syndrome 2; Breast Cancer; Prostate Cancer; Osteogenic Sarcoma

All of MyBioSource's Products are for scientific laboratory research purposes and are not for diagnostic, therapeutics, prophylactic or in vivo use. Through your purchase, you expressly represent and warrant to MyBioSource that you will properly test and use any Products purchased from MyBioSource in accordance with industry standards. MyBioSource and its authorized distributors reserve the right to refuse to process any order where we reasonably believe that the intended use will fall outside of our acceptable guidelines.

While every efforts were made to ensure the accuracy of the information provided in this datasheet, MyBioSource will not be liable for any omissions or errors contained herein. MyBioSource reserves the right to make changes to this datasheet at any time without prior notice.

It is the responsibility of the customer to report product performance issues to MyBioSource within 30 days of receipt of the product. Please visit our Terms & Conditions page for more information.